Abstract
Thymic neoplasms are chemotherapy-sensitive tumors with a 30–50% 5-year survival in previously untreated patients. Responses in small series have been reported with single-agent doxorubicin, cisplatin, etoposide, ifosfamide, and corticosteroids (Table 26.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Macchiarini P, Chella A, Ducci F et al (1991) Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 68:706–713
Rea F, Sartori F, Loy M et al (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106(3):543–549
Kim ES, Putnam JB Jr, Komaki R et al (2004) A phase II study of a multidisciplinary approach with induction chemotherapy (IC), followed by surgical resection (SR), radiation therapy (RT) and consolidation chemotherapy for unresectable malignant thymoma. Final report. Lung Cancer 44:369–379
Lucchi M, Ambrogi MC, Duranti L et al (2005) Advanced stage thymomas and thymic carcinomas: Results of multimodality treatments. Ann Thorac Surg 79(6):1840–1844
Huang J, Rizk N, Park B et al (2007) Recent clinical experience with multimodality therapy in thymic carcinoma. Proc ASCO 2007 (absract 18007)
Venuta F, Rendina EA, Pescarmona EO et al (1997) Multimodality treatment of thymoma: A prospective study. Ann Thorac Surg 64:1585–1592
Venuta F, Rendina EA, De Giacomo T et al (1998) Severe postoperative hemorrhage after neoadjuvant chemotherapy for invasive thymoma. Ann Thorac Surg 66:981–982
Loehrer PJ Sr, Chen M, Kim K et al (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. J Clin Oncol 15(9):3093–3099
Shin DM, Walsh GL, Komaki R et al (1998) A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 129(2):100–104
Jacot W, Quantin X, Valette S et al (2005) Multimodality treatment program in invasive thymic epithelial tumor. Am J Clin Oncol 28(1):5–7
Iwasaki Y, Ohsugi S, Takemura Y et al (2002) Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma. Chest 122:2249–2252
Highley MS, Underhill CR, Parnis FX et al (1999) Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737–2744
Hejna M, Haberl I, Raderer M (1999) Nonsurgical management of malignant thymoma. Cancer 85:1871–1884
Fornasiero A, Daniele O, Ghiotto C et al (1991) Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68(1):30–33
Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14(3):814–820
Loehrer PJ Sr, Jiroutek M, Aisner S et al (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial. Cancer 91(11):2010–2015
Kunitoh H, Tamura T, Fukuda H et al (2006) Dose intensive chemotherapy (Cx) in advanced thymoma: Initial report of Japan Clinical Oncology Group trials (JCOG 9605 and 9606) Proc ASCO 2006 (abstract 7080)
Loehrer PJ Sr, Kim K, Aisner SC et al (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12(6):1164–1168
Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Proc ASCO 2006 (abstract 7079)
Hanna N, Gharpure VS, Abonour R et al (2001) High-dose carboplatin with etoposide in patients with recurrent thymoma: The Indiana University experience. Bone Marrow Transpl 28:435–438
Palmieri G, Montella L, Martignetti A et al (2002) Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 94:1414–1420
Loehrer PJ Sr, Wang W, Johnson DH et al (2004) Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 22:293–299
Tetsuya O, Horoyuki A, Kato D et al (2004) Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 50:279–282
Farina G, Garassino MC, Gambacorta M et al (2007) Response of thymoma to Cetuximab. Lancet Oncol 8:449–450
Chuah C, Lim TH, Lim AS et al (2006) Dasatinib induces a response in malignant thymoma. J Clin Oncol 34:56–58
Taguchi T, Suehiro T, Toru K et al (2006) Pleural dissemination of thymoma showing tumor regression after combined corticosteroid and tacrolimus therapy. Eur J Int Med 8:575–577
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Italia
About this chapter
Cite this chapter
Conte, P.F., Barbieri, F. (2008). Chemotherapy in Thymic Neoplasms. In: Lavini, C., Moran, C.A., Morandi, U., Schoenhuber, R. (eds) Thymus Gland Pathology. Springer, Milano. https://doi.org/10.1007/978-88-470-0828-1_26
Download citation
DOI: https://doi.org/10.1007/978-88-470-0828-1_26
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0827-4
Online ISBN: 978-88-470-0828-1
eBook Packages: MedicineMedicine (R0)